Optimal adjuvant endocrine therapy for breast cancer

Lancet Oncol. 2021 Oct;22(10):1357-1358. doi: 10.1016/S1470-2045(21)00420-4. Epub 2021 Sep 17.

Authors

Rachel L Yung¹, Nancy E Davidson²

Affiliations

¹ Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA.
² Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA. Electronic address: ndavidson@fredhutch.org.

PMID: 34543612
DOI: 10.1016/S1470-2045(21)00420-4

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents, Hormonal / adverse effects
Breast Neoplasms* / drug therapy
Female
Humans
Tamoxifen / adverse effects

Substances

Antineoplastic Agents, Hormonal
Tamoxifen